How does comorbid attention-deficit/hyperactivity disorder (ADHD) affect individuals with substance use disorder (SUD)? Is treatment for ADHD associated with retention in outpatient SUD therapy?
Although the tetralogy of Fallot (TOF) may be associated with psychiatric disorders, the risk of this association has not been well documented. This nationwide cohort study investigated the long-term risk of psychiatric disorders in TOF patients.
Adult ADHD presents unique challenges for primary care providers. Thus, volunteer primary care and mental health providers created an Adult ADHD Toolkit with information on ADHD and treatment. This study assessed the impact of toolkit implementation.
Have you wondered why people act impulsively or compulsively? Have you been frustrated when strategies to change behaviors are unsuccessful? If so, then this article may prove useful by providing insights into intrusive-destructive behaviors.
Do you have patients who take ADHD medication and are planning a pregnancy? How do you respond to questions of safety? This journal CME activity offers evidence.
This study used post hoc path analyses to examine reciprocal relationships between improvement in executive function and ADHD symptoms from a double-blind, placebo-controlled study of lisdexamfetamine in adults with ADHD. Read on to find out more.
Existing treatments for attention-deficit/hyperactivity disorder (ADHD) in adults, though effective, have limitations. This study examined the efficacy and safety of guanfacine extended-release in adults with ADHD.
This report describes an unusual case of severe depression that developed as a result of a series of neurologic insults, starting with a stroke that was followed by a rare form of seizures, lateralized periodic discharges. Read on to find out more.
In this letter to the editor, the author attempts to speculate on the link between autism spectrum disorder and gender dysphoria. Read on to find out more.
Children with ADHD often have functional impairments in the early morning and late afternoon and evening. This study sought to establish norms on 2 rating scales to help clinicians determine when such impairments are clinically significant.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT